Your browser doesn't support javascript.
loading
Efficacy and Economic Evaluation of Tramadol and Hydromorphone Combined with Flurbiprofen Axetil in the Treatment of PCIA for Postoperative Cesarean / 中国药学杂志
Chinese Pharmaceutical Journal ; (24): 652-658, 2018.
Article Dans Chinois | WPRIM | ID: wpr-858370
ABSTRACT

OBJECTIVE:

To evaluate the efficacy, safety and economy of tramadol and hydromorphone combined with flurbiprofen axetil in the treatment of PCIA for postoperative cesarean through the empirical study, optimize the drug treatment program and provide certain evidence-based medicine and pharmacoeconomics basis for clinical use of drugs.

METHODS:

Included 240 cases of maternal, these maternal need to use PCIA for postoperative analgesia and meet the inclusion and exclusion criteria. The maternal samples included in the study were divided into two groups tramadol(tramadol 2 mg •kg-1 + flurbiprofen axetil 5 mg•kg-1) and hydromorphone(hydromorphone 0.04 mg •kg-1 + flurbiprofen axetil 5 mg•kg-1). The efficacy index, safety index and cost index of the two groups were observed. The effectiveness, adverse reactions and cost data were collected. Statistical analysis and cost effectiveness analysis were used to evaluate the economic effects of the two groups.

RESULTS:

The analgesic effect of tramadol group was same as the hydromorphone group, but the total cost of analgesia in tramadol group was lower than that in hydromorphone group, the results of the minimum cost analysis showed that the tramadol regimen was superior and the results were stable.

CONCLUSION:

The PCIA regimen of tramadol group is superior to that of the hydromorphone group, considering the efficacy, safety and economy.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Évaluation en économique de la santé langue: Chinois Texte intégral: Chinese Pharmaceutical Journal Année: 2018 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Type d'étude: Évaluation en économique de la santé langue: Chinois Texte intégral: Chinese Pharmaceutical Journal Année: 2018 Type: Article